AbClon Completes Enrollment for Phase 2 Clinical Trial of CAR-T Therapy Nespecell
On July 3, AbClon announced that it has completed the enrollment of patients for the Phase 2 clinical trial of Nespecell (AT101), its chimeric antigen receptor T-cell (CAR-T) therapy, for patients with relapsed or refractory hematologic malignancies.
AT101, unlike global CAR-T therapies that commonly use the FMC63 antibody, incorporates h1218, a core antibody independently developed by AbClon. In previously announced interim results from the Phase 2 trial, AT101 demonstrated an objective response rate (ORR) of 94% and a complete remission (CR) rate of 68%, indicating the complete disappearance of cancer cells.
With the conclusion of patient recruitment, AbClon plans to complete all administrations, derive the final clinical data within this year, and apply for accelerated approval (product authorization). The company had previously been designated as a 'development-stage orphan drug' and selected as an eligible candidate for 'Global Innovative Product Fast-Track Review (GIFT)' by the Ministry of Food and Drug Safety.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A company representative stated, "Through rigorous final data validation, we aim to successfully complete product authorization and strive to provide a new treatment option to hematologic cancer patients worldwide as soon as possible."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.